Retrieve available abstracts of 60 articles: HTML format
Single Articles
June 2025
HUANG BJ, Meyer LK, Alonzo TA, Wang YC, et al Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From
the Children's Oncology Group.
J Clin Oncol. 2025;43:1961-1971. PubMedAbstract available
SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or
Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
J Clin Oncol. 2025 Jun 6:JCO2500166. doi: 10.1200/JCO-25-00166. PubMedAbstract available
May 2025
SHADMAN M, Munir T, Ma S, Lasica M, et al Zanubrutinib and Venetoclax for Patients With Treatment-Naive Chronic Lymphocytic
Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation:
SEQUOIA Arm D Results.
J Clin Oncol. 2025 May 31:JCO2500758. doi: 10.1200/JCO-25-00758. PubMedAbstract available
April 2025
KIRKWOOD AA, Goulden N, Moppett J, Samarasinghe S, et al High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic
Lymphoma: Results of the Randomized Phase III Study UKALL 2011.
J Clin Oncol. 2025 Apr 7:JCO2401851. doi: 10.1200/JCO-24-01851. PubMedAbstract available
March 2025
DAVIDS MS, Ryan CE, Lampson BL, Ren Y, et al Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a
Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk
Disease.
J Clin Oncol. 2025 Mar 18:JCO2500466. doi: 10.1200/JCO-25-00466. PubMed
TREGNAGO C, Benetton M, Ries RE, Peplinski JH, et al Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An
AIEOP-BFM and COG-SWOG Intergroup Collaboration.
J Clin Oncol. 2025;43:972-984. PubMedAbstract available
February 2025
RUSSELL NH, Thomas A, Hills RK, Thomas I, et al Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or
Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in
Older Patients With AML: Results From the NCRI AML18 Trial.
J Clin Oncol. 2025;43:694-704. PubMedAbstract available
KATO M, Okamoto Y, Imamura T, Kada A, et al JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone
Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.
J Clin Oncol. 2025;43:567-577. PubMedAbstract available
ROLOFF GW, Aldoss I, Kopmar NE, Lin C, et al Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for
Adults With Relapsed/Refractory B-Cell ALL.
J Clin Oncol. 2025;43:558-566. PubMedAbstract available
January 2025
GYURKOCZA B, Nath R, Seropian S, Choe H, et al Randomized Phase III SIERRA Trial of (131)I-Apamistamab Before Allogeneic
Hematopoietic Cell Transplantation Versus Conventional Care for
Relapsed/Refractory AML.
J Clin Oncol. 2025;43:201-213. PubMedAbstract available
December 2024
KANTARJIAN H, Short NJ, Haddad FG, Jain N, et al Results of the Simultaneous Combination of Ponatinib and Blinatumomab in
Philadelphia Chromosome-Positive ALL.
J Clin Oncol. 2024;42:4246-4251. PubMedAbstract available
ROY A, Brander DM, Hill EG, Halabi S, et al Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point
Evaluation for Chronic Lymphocytic Leukemia.
J Clin Oncol. 2024 Dec 12:JCO2401881. doi: 10.1200/JCO-24-01881. PubMed
SHADMAN M, Munir T, Robak T, Brown JR, et al Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up
of SEQUOIA.
J Clin Oncol. 2024 Dec 8:JCO2402265. doi: 10.1200/JCO-24-02265. PubMedAbstract available
DAVIDS MS, Ryan CE, Lampson BL, Ren Y, et al Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a
Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk
Disease.
J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503. PubMedAbstract available
VERSLUIS J, Metzner M, Wang A, Gradowska P, et al Risk Stratification in Older Intensively Treated Patients With AML.
J Clin Oncol. 2024;42:4084-4094. PubMedAbstract available
November 2024
LANGERBEINS P, Robrecht S, Nieper P, Cramer P, et al Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized,
Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
J Clin Oncol. 2024 Nov 27:JCO2400975. doi: 10.1200/JCO.24.00975. PubMedAbstract available
HEIKAMP EB, Armstrong SA Revumenib Revises the Treatment Landscape for KMT2A-r Leukemia.
J Clin Oncol. 2024 Nov 7:JCO2401265. doi: 10.1200/JCO-24-01265. PubMed
October 2024
CHEVALLIER P, Leguay T, Delord M, Salek C, et al Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly
Diagnosed CD22(+) Philadelphia Chromosome-Negative B-Cell Precursor Acute
Lymphoblastic Leukemia.
J Clin Oncol. 2024 Oct 17:JCO2400490. doi: 10.1200/JCO.24.00490. PubMedAbstract available
September 2024
ROLLIG C, Steffen B, Schliemann C, Mikesch JH, et al Single or Double Induction With 7 + 3 Containing Standard or High-Dose
Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the
Study Alliance Leukemia.
J Clin Oncol. 2024 Sep 16:JCO2400235. doi: 10.1200/JCO.24.00235. PubMedAbstract available
KIM R, Chalandon Y, Rousselot P, Cayuela JM, et al Significance of Measurable Residual Disease in Adult Philadelphia
Chromosome-Positive ALL: A GRAAPH-2014 Study.
J Clin Oncol. 2024;42:3140-3150. PubMedAbstract available
VALLEJO BA, Ansari A, Parikh SA, Achenbach SJ, et al Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell
Lymphocytosis.
J Clin Oncol. 2024 Sep 4:JCO2400332. doi: 10.1200/JCO.24.00332. PubMedAbstract available
August 2024
SIMON F, Ligtvoet R, Robrecht S, Cramer P, et al Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia.
J Clin Oncol. 2024 Aug 30:JCO2401192. doi: 10.1200/JCO.24.01192. PubMedAbstract available
CHANG TC, Chen W, Qu C, Cheng Z, et al Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.
J Clin Oncol. 2024 Aug 9:JCO2302238. doi: 10.1200/JCO.23.02238. PubMedAbstract available
ISSA GC, Aldoss I, Thirman MJ, DiPersio J, et al Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute
Leukemia (AUGMENT-101).
J Clin Oncol. 2024 Aug 9:JCO2400826. doi: 10.1200/JCO.24.00826. PubMedAbstract available
YOSHIMURA S, Li Z, Gocho Y, Yang W, et al Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute
Lymphoblastic Leukemia.
J Clin Oncol. 2024 Aug 5:JCO2400500. doi: 10.1200/JCO.24.00500. PubMedAbstract available
TURCOTTE LM, Neglia JP Duress and Distress Versus a Neurocognitive Mess: The Challenges of Procedural
Sedation in Pediatric B-ALL.
J Clin Oncol. 2024;42:2628-2631. PubMedAbstract available
ALEXANDER S, Kairalla JA, Gupta S, Hibbitts E, et al Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk
B ALL: A Children's Oncology Group Study.
J Clin Oncol. 2024;42:2671-2679. PubMedAbstract available
July 2024
MATAVA CT, Peyton J, von Ungern-Sternberg BS, Ing C, et al Propofol, Anesthesia, and Neurocognitive Outcomes in Patients With Pediatric
Leukemia: Are We Missing the Forest for the Trees?
J Clin Oncol. 2024 Jul 24:JCO2400856. doi: 10.1200/JCO.24.00856. PubMed
June 2024
TIERENS A, Arad-Cohen N, Cheuk D, De Moerloose B, et al Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With
Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
J Clin Oncol. 2024;42:2174-2185. PubMedAbstract available
TIONG IS, Hiwase DK, Abro E, Bajel A, et al Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With
Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
J Clin Oncol. 2024;42:2161-2173. PubMedAbstract available
KITTAI AS, Bond D, Huang Y, Bhat SA, et al Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An
International, Multicenter, Retrospective Study.
J Clin Oncol. 2024;42:2071-2079. PubMedAbstract available
REED DR, Tulpule A, Metts J, Trucco M, et al Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma
Trials.
J Clin Oncol. 2024 Jun 6:JCO2302717. doi: 10.1200/JCO.23.02717. PubMedAbstract available
May 2024
DAVER NG, Craddock C Moving Toward Total Therapy in AML: Personalized Treatments Improve
Post-Transplant Outcome.
J Clin Oncol. 2024;42:1731-1733. PubMed
WANG ES, Goldberg AD, Tallman M, Walter RB, et al Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated
AML.
J Clin Oncol. 2024;42:1776-1787. PubMedAbstract available
VAN DER SLUIS IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, et al Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric
ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
J Clin Oncol. 2024;42:1676-1686. PubMedAbstract available
SHORT NJ, Daver N, Dinardo CD, Kadia T, et al Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or
Refractory FLT3-Mutated AML.
J Clin Oncol. 2024;42:1499-1508. PubMedAbstract available
April 2024
TOBIASSON M, Pandzic T, Illman J, Nilsson L, et al Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients
With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell
Transplantation.
J Clin Oncol. 2024;42:1378-1390. PubMedAbstract available
RUSSELL NH, Wilhelm-Benartzi C, Othman J, Dillon R, et al Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin
With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With
Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3
Mutations.
J Clin Oncol. 2024;42:1158-1168. PubMedAbstract available
March 2024
BERMAN E, Shah NP, Deninger M, Altman JK, et al CML and the WHO: Why?
J Clin Oncol. 2024;42:984-986. PubMed
FEDELE PL, Opat S Chronic Lymphocytic Leukemia-Time to Care for the Survivors.
J Clin Oncol. 2024 Mar 15:JCO2302738. doi: 10.1200/JCO.23.02738. PubMed
LEVIS MJ, Hamadani M, Logan B, Jones RJ, et al Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With
Internal Tandem Duplication Mutation of FLT3.
J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474. PubMedAbstract available
MAHON FX, Pfirrmann M, Dulucq S, Hochhaus A, et al European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid
Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free
Remission.
J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647. PubMedAbstract available
FOA R, Bassan R, Elia L, Piciocchi A, et al Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult
Philadelphia-Positive ALL.
J Clin Oncol. 2024;42:881-885. PubMedAbstract available
CONTER V, Valsecchi MG, Cario G, Zimmermann M, et al Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the
AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in
High-Risk ALL: Results of a Randomized Study.
J Clin Oncol. 2024;42:915-926. PubMedAbstract available
HODDER A, Mishra AK, Enshaei A, Baird S, et al Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.
J Clin Oncol. 2024;42:907-914. PubMedAbstract available
January 2024
LOGAN A Innovating Simpler and Less Toxic Frontline Management for Adults With ALL.
J Clin Oncol. 2024;42:250-252. PubMed
STELLJES M, Raffel S, Alakel N, Wasch R, et al Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With
Philadelphia Chromosome-Negative B-Precursor ALL.
J Clin Oncol. 2024;42:273-282. PubMedAbstract available
STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and
Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for
T1aN0 Non-Small-Cell Lung Cancer.
J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306. PubMedAbstract available
December 2023
PIETERS R, Mullighan CG, Hunger SP Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.
J Clin Oncol. 2023;41:5579-5591. PubMedAbstract available
LEE SHR, Ashcraft E, Yang W, Roberts KG, et al Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL.
J Clin Oncol. 2023;41:5422-5432. PubMedAbstract available
RASHIDI A, Ebadi M, Rehman TU, Elhusseini H, et al Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus
Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
J Clin Oncol. 2023;41:5306-5319. PubMedAbstract available
November 2023
BRIVIO E, Pennesi E, Willemse ME, Huitema ADR, et al Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase
Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG
AAML1921.
J Clin Oncol. 2023 Nov 30:JCO2300897. doi: 10.1200/JCO.23.00897. PubMedAbstract available
RAETZ EA, Rebora P, Conter V, Schrappe M, et al Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in
Contemporary Trials.
J Clin Oncol. 2023;41:5025-5034. PubMedAbstract available
DAVER NG, Vyas P, Kambhampati S, Al Malki MM, et al Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody
Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML:
Phase Ib Results.
J Clin Oncol. 2023;41:4893-4904. PubMedAbstract available
LI J, Gao J, Liu A, Liu W, et al Homoharringtonine-Based Induction Regimen Improved the Remission Rate and
Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol
Study.
J Clin Oncol. 2023;41:4881-4892. PubMedAbstract available
October 2023
DEWOLF S, Tallman MS, Rowe JM, Salman MY, et al What Influences the Decision to Proceed to Transplant for Patients With AML in
First Remission?
J Clin Oncol. 2023;41:4693-4703. PubMedAbstract available
LING Y, Xuan L, Xu N, Huang F, et al Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML
Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter
Randomized Phase III Trial.
J Clin Oncol. 2023;41:4632-4642. PubMedAbstract available
September 2023
MCCAW ZR, Richardson PG, Wei LJ Assessing the Ability of Long Noncoding RNA Expression to Predict Patient
Outcomes in Pediatric AML.
J Clin Oncol. 2023;41:4446-4447. PubMed
Erratum: Clinical Implications of Minimal Residual Disease Detection in Infants
With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06
Protocol.
J Clin Oncol. 2023 Sep 12:JCO2301844. doi: 10.1200/JCO.23.01844. PubMed
PRATZ KW, Cherry M, Altman JK, Cooper BW, et al Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as
Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
J Clin Oncol. 2023;41:4236-4246. PubMedAbstract available